Propanc Biopharma Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 20, 2024
PPCB$1.76-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
The following unaudited interim condensed consolidated financial statements of Propanc Biopharma, Inc. are included in this Quarterly Report on Form 10-Q:
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Condensed Consolidated Balance Sheets at December 31, 2023 (unaudited) and June 30, 2023 | F-2 |
|---|---|
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended December 31, 2023 and 2022 (unaudited) | F-3 |
| Condensed Consolidated Statements of Changes in Stockholders’ Deficit for each of the three and six months in the periods ended December 31, 2023 and 2022 (unaudited) | F-4 |
| Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2023 and 2022 (unaudited) | F-5 |
| Notes to the Condensed Consolidated Financial Statements (unaudited) | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.